- Home
- COLL vs CRF Comparison
COLL vs CRF Comparison
Compare COLL & CRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COLL | CRF |
|---|---|---|
| Founded | 2002 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | COLL | CRF |
|---|---|---|
| Price | $45.38 | $7.96 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $51.17 | N/A |
| AVG Volume (30 Days) | 512.5K | ★ 1.1M |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 18.10% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | 1.40 |
| Revenue | ★ $757,067,000.00 | $11,461,786.00 |
| Revenue This Year | $26.17 | N/A |
| Revenue Next Year | $3.65 | N/A |
| P/E Ratio | $28.19 | ★ $5.38 |
| Revenue Growth | ★ 26.34 | 6.53 |
| 52 Week Low | $23.23 | $5.70 |
| 52 Week High | $50.79 | $9.56 |
Technical Indicators
Market Signals| Indicator | COLL | CRF |
|---|---|---|
| Relative Strength Index (RSI) | 44.14 | 45.72 |
| Support Level | $44.43 | $7.98 |
| Resistance Level | $48.29 | $8.00 |
| Average True Range (ATR) | 2.15 | 0.05 |
| MACD | -0.25 | -0.02 |
| Stochastic Oscillator | 31.27 | 18.00 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.